Cardioprotection during chemotherapy: Need for faster transfer of knowledge from cardiology to oncology and role for a cardio-oncologist

Journal of the American College of Cardiology

Volumn 61, Issue 23, 2013, Pages 2363-2364

  Smiseth, Otto A ^a,b,c   Edvardsen, Thor ^a,d   Skulstad, Helge ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b K G Jebsen Cardiac Research Centre   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

cardiac toxicity; carvedilol; chemotherapy; enalapril; left ventricular dysfunction

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; TRASTUZUMAB;

CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE;

EID: 84878740981     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.02.073     Document Type: Editorial

References (15)

1. E.T.H. Yeh, A.T. Tong, and D.J. Lenihan Cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management Circulation 109 2004 3122 3131
2. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials Cancer 97 2003 2869 2879 (Pubitemid 36605157)
3. R.S. Jiji, C.M. Kramer, and M. Salerno Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs J Nucl Cardiol 19 2012 377 388
4. V. Guarneri, D.J. Lenihan, and V. Valero Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience J Clin Oncol 24 2006 4107 4115 (Pubitemid 46622286)
5. I. Smith, M. Procter, and R.D. Gelber 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial Lancet 369 2007 29 36 (Pubitemid 46039831)
6. D. Slamon, W. Eiermann, and N. Robert Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
7. T.M. Suter, and M.S. Ewer Cancer drugs and the heart: importance and management Eur Heart J 34 2013 1102 1111
8. D. Cardinale, A. Colombo, and G. Lamantia Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 2010 213 220
9. H. Nakamae, K. Tsumura, and Y. Terada Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 2005 2492 2498 (Pubitemid 41691573)
10. N. Kalay, E. Basar, and I. Osdogry Protective effects of carvedilol against anthracyclines-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262 (Pubitemid 44855419)
11. X. Bosch, M. Rovira, and M. Sitges Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies) J Am Coll Cardiol 61 2013 2355 2362
12. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 2005 e1 e82 erratum in J Am Coll Cardiol 2006;47:1503-5.
13. A. Hjalmarson, S. Goldstein, B. Fagerberg MERIT-HF Study Group Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF) JAMA 283 2000 1295 1302 (Pubitemid 30129796)
14. R. Garg, S. Yusuf Collaborative Group on ACE Inhibitor Trials Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 273 1995 1450 1456
15. W. Kosmala, M. Przewlocka-Kosmala, and H. Szczepanik-Osadnik A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome J Am Coll Cardiol Img 4 2011 1239 1249